Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Seres Therapeutics, Inc.MCRB · Entity 7191 | Chief Medical Officer and EVP | January 25, 2019 | January 29, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Seres Therapeutics, Inc.
Report date January 25, 2019 · Filed January 29, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| STOCK OPTION (RIGHT TO BUY)SEC Table II · derivative / convertible security · Conversion / exercise price $6.01 · Expires 2029-01-24 | Direct | 30,000 |
Reported balance
After 2019-01-25 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-01-25 · Grant · Acquired 30,000 · Balance 30,000 F1: The option will vest as to 25% of the shares on January 25, 2020. The remainder of the shares will vest in 12 equal quarterly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: The option will vest as to 25% of the shares on January 25, 2020. The remainder of the shares will vest in 12 equal quarterly installments thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 25, 2019 Filed Jan 29, 2019 18:55 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | GrantSTOCK OPTION (RIGHT TO BUY) · Derivative | 30,000 | $0.00 Strike: $6.01 | $0.00 |
DisclosureSEC source: 0000899243-19-002142 · doc4.xml · derivative · entry 1 HORGAN KEVIN · CIK 0001510614 · Chief Medical Officer and EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2029-01-24 F1 · derivative.exercise_date: The option will vest as to 25% of the shares on January 25, 2020. The remainder of the shares will vest in 12 equal quarterly installments thereafter. Read SEC document |
| October 23, 2018 Filed Oct 24, 2018 17:58 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | GrantStock Option (right to buy) · Derivative | 225,000 | $0.00 Strike: $6.58 | $0.00 |
DisclosureSEC source: 0000899243-18-027399 · doc4.xml · derivative · entry 1 HORGAN KEVIN · CIK 0001510614 · Chief Medical Officer and EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,000 Underlying: Common Stock · 225,000 shares Expires 2028-10-22 F1 · derivative.exercise_date: The Option will vest as to 25% of the shares on October 22, 2019. The remainder of the shares will vest in 12 equal quarterly installments thereafter Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.